Skip to main content
Erschienen in: CNS Drugs 7/2011

01.07.2011 | Review Article

Issues in the Management of Challenging Behaviours of Adults with Autism Spectrum Disorder

verfasst von: Prof. Johnny L. Matson, PhD, Megan Sipes, Jill C. Fodstad, Mary E. Fitzgerald

Erschienen in: CNS Drugs | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Autism spectrum disorder (ASD) is a particularly important risk factor for challenging behaviours such as aggression, tantrums, self-injury and pica. Adults with ASD have rarely been studied with respect to these problems. This is particularly disconcerting since there are far more adults than children with ASD. In addition, because of adults’ increased physical size and longer history of these problems, treating these behaviours effectively is important.
Psychological methods, particularly applied behaviour analysis, and pharmacotherapy have been the most frequently addressed treatments for challenging behaviours associated with ASD in the research literature. In many cases, challenging behaviours have clear environmental antecedents. In these cases, behavioural interventions, such as applied behaviour analysis, should be used to reduce the behaviours. When environmental factors cannot be identified or when challenging behaviours are very severe, pharmacological treatments may be necessary in combination with behavioural interventions. Newer antipsychotics are the most researched medications for use with this population. Currently, risperidone and aripiprazole are the only medications that have US FDA approval for the treatment of behaviours associated with ASD, specifically irritability; however, they are indicated for use in children not adults. It is important not to use medications unnecessarily, due to possible side effects associated with their use.
Based on available research, some recommendations for the treatment of challenging behaviours of adults (and children) with ASD include the use of functional assessment, side-effect monitoring of medications and behavioural methods whenever possible. Additionally, future research in this area needs to focus more on adults, as most current research has used child samples.
Literatur
1.
Zurück zum Zitat Matson J. Determining treatment outcomes in early intervention programs for autism spectrum disorders: a critical analysis of measurement issues in learning based interventions. Res Dev Disabil 2007; 28(2): 207–18PubMedCrossRef Matson J. Determining treatment outcomes in early intervention programs for autism spectrum disorders: a critical analysis of measurement issues in learning based interventions. Res Dev Disabil 2007; 28(2): 207–18PubMedCrossRef
3.
Zurück zum Zitat Lin JD, Lin LP, Wu JL. Administrative prevalence of autism spectrum disorders based on national disability registers in Taiwan. J Autism Dev Disord 2009; 3(1): 269–74 Lin JD, Lin LP, Wu JL. Administrative prevalence of autism spectrum disorders based on national disability registers in Taiwan. J Autism Dev Disord 2009; 3(1): 269–74
4.
Zurück zum Zitat Marriage S, Wolverton A, Marriage K. Autism spectrum disorders grown up: a chart review of adult functioning. J Can Acad Child Adolesc Psychiatry 2009; 18(4): 322–8PubMed Marriage S, Wolverton A, Marriage K. Autism spectrum disorders grown up: a chart review of adult functioning. J Can Acad Child Adolesc Psychiatry 2009; 18(4): 322–8PubMed
5.
Zurück zum Zitat Newschaffer CJ, Falb MD, Gurney JG. National autism prevalence trends from United States special education data. Pediatrics 2005; 115(3): e227–81CrossRef Newschaffer CJ, Falb MD, Gurney JG. National autism prevalence trends from United States special education data. Pediatrics 2005; 115(3): e227–81CrossRef
6.
Zurück zum Zitat Matson JL, LoVullo SV. Trends and topics in autism spectrum disorders research. Res Autism Spectr Disord 2009; 3(1): 252–7CrossRef Matson JL, LoVullo SV. Trends and topics in autism spectrum disorders research. Res Autism Spectr Disord 2009; 3(1): 252–7CrossRef
7.
Zurück zum Zitat Emerson E, Bromley J. The form and function of challenging behaviors. J Intellect Disabil Res 1995; 39(5): 388–98PubMedCrossRef Emerson E, Bromley J. The form and function of challenging behaviors. J Intellect Disabil Res 1995; 39(5): 388–98PubMedCrossRef
8.
Zurück zum Zitat McClean B, Grey I. Modifying challenging behavior and planning positive supports. In: Carr A, O’Reilly G, Noonan Walsh P, et al., editors. The handbook of intellectual disability and clinical psychology practice. New York (NY): Routledge, 2007: 643–84 McClean B, Grey I. Modifying challenging behavior and planning positive supports. In: Carr A, O’Reilly G, Noonan Walsh P, et al., editors. The handbook of intellectual disability and clinical psychology practice. New York (NY): Routledge, 2007: 643–84
9.
Zurück zum Zitat Emerson E, Kiernan C, Alborz A, et al. The prevalence of challenging behaviors: a total population study. Res Dev Disabil 2001; 22: 77–93PubMedCrossRef Emerson E, Kiernan C, Alborz A, et al. The prevalence of challenging behaviors: a total population study. Res Dev Disabil 2001; 22: 77–93PubMedCrossRef
10.
Zurück zum Zitat Ben-Itzchak E, Zachor DA. The effects of intellectual functioning and autism severity on outcome of early behavioral intervention for children with autism. Res Dev Disabil 2007; 28(3): 287–303PubMedCrossRef Ben-Itzchak E, Zachor DA. The effects of intellectual functioning and autism severity on outcome of early behavioral intervention for children with autism. Res Dev Disabil 2007; 28(3): 287–303PubMedCrossRef
11.
Zurück zum Zitat McClintock K, Hall S, Oliver C. Risk markers associated with challenging behaviors in people with intellectual disabilities: a meta-analytic study. J Intellect Disabil Res 2003; 47(6): 405–16PubMedCrossRef McClintock K, Hall S, Oliver C. Risk markers associated with challenging behaviors in people with intellectual disabilities: a meta-analytic study. J Intellect Disabil Res 2003; 47(6): 405–16PubMedCrossRef
12.
Zurück zum Zitat Sigafoos J. Communication development and aberrant behavior in children with developmental disabilities. Educ Train Mental Retard Develop Disabil 2000; 35(2): 168–76 Sigafoos J. Communication development and aberrant behavior in children with developmental disabilities. Educ Train Mental Retard Develop Disabil 2000; 35(2): 168–76
13.
Zurück zum Zitat Matson JL. Aggression and tantrums in children with autism: a review of behavioral treatments and maintaining variables. J Ment Health Res Intellect Disabil 2009; 2(3): 169–87CrossRef Matson JL. Aggression and tantrums in children with autism: a review of behavioral treatments and maintaining variables. J Ment Health Res Intellect Disabil 2009; 2(3): 169–87CrossRef
14.
Zurück zum Zitat Horner RH, Carr EG, Strain PS, et al. Problem behavior interventions for young children with autism: a research synthesis. J Autism Dev Disord 2002; 32(5): 423–46PubMedCrossRef Horner RH, Carr EG, Strain PS, et al. Problem behavior interventions for young children with autism: a research synthesis. J Autism Dev Disord 2002; 32(5): 423–46PubMedCrossRef
15.
Zurück zum Zitat McCarthy J, Hemmings C, Kravariti E, et al. Challenging behaviors and co-morbid psychopathology in adults with intellectual disability and autism spectrum disorders. Res Dev Disabil 2010; 31(2): 362–6PubMedCrossRef McCarthy J, Hemmings C, Kravariti E, et al. Challenging behaviors and co-morbid psychopathology in adults with intellectual disability and autism spectrum disorders. Res Dev Disabil 2010; 31(2): 362–6PubMedCrossRef
16.
Zurück zum Zitat Graetz JE. Autism grows up: opportunities for adults with autism. Disabil Soc 2010; 25(1): 33–47CrossRef Graetz JE. Autism grows up: opportunities for adults with autism. Disabil Soc 2010; 25(1): 33–47CrossRef
17.
Zurück zum Zitat Sturmey P, Lott JD, Laud RB, et al. Correlates of restraint use in an institutional population: a replication. J Intellectual Disabil Res 2005; 49(3): 501–6CrossRef Sturmey P, Lott JD, Laud RB, et al. Correlates of restraint use in an institutional population: a replication. J Intellectual Disabil Res 2005; 49(3): 501–6CrossRef
18.
Zurück zum Zitat Lee LC, Harrington RA, Chang JJ, et al. Increased risk of injury in children with developmental disabilities. Res Dev Disabil 2008; 29(3): 247–55PubMedCrossRef Lee LC, Harrington RA, Chang JJ, et al. Increased risk of injury in children with developmental disabilities. Res Dev Disabil 2008; 29(3): 247–55PubMedCrossRef
19.
Zurück zum Zitat Herzinger CV, Campbell JM. Comparing functional assessment methodologies: a quantitative synthesis. J Autism Dev Disord 2007; 37(8): 1430–45PubMedCrossRef Herzinger CV, Campbell JM. Comparing functional assessment methodologies: a quantitative synthesis. J Autism Dev Disord 2007; 37(8): 1430–45PubMedCrossRef
20.
Zurück zum Zitat Sturmey P, Seiverling L, Ward-Horner J. Assessment of challenging behaviors in people with autism spectrum disorders. In: Matson JL, editor. Clinical assessment and interventions for autism spectrum disorders. New York (NY): Springer, 2009: 131–64 Sturmey P, Seiverling L, Ward-Horner J. Assessment of challenging behaviors in people with autism spectrum disorders. In: Matson JL, editor. Clinical assessment and interventions for autism spectrum disorders. New York (NY): Springer, 2009: 131–64
21.
Zurück zum Zitat Matson JL, Mahan S, Hess JA, et al. Progression of challenging behaviors in children and adolescents with autism spectrum disorder as measured by the Autism Spectrum Disorders-Problem Behaviors for Children (ASD-PBC). Res Autism Spectr Disord 2010; 4(3): 400–4CrossRef Matson JL, Mahan S, Hess JA, et al. Progression of challenging behaviors in children and adolescents with autism spectrum disorder as measured by the Autism Spectrum Disorders-Problem Behaviors for Children (ASD-PBC). Res Autism Spectr Disord 2010; 4(3): 400–4CrossRef
22.
Zurück zum Zitat Chowdhury M, Benson BA, Hillier A. Changes in restricted repetitive behaviors with age: a study of high-functioning adults with autism spectrum disorders. Res Autism Spectr Disord 2010; 4(2): 210–6CrossRef Chowdhury M, Benson BA, Hillier A. Changes in restricted repetitive behaviors with age: a study of high-functioning adults with autism spectrum disorders. Res Autism Spectr Disord 2010; 4(2): 210–6CrossRef
23.
Zurück zum Zitat Stigler KA, McDougle CJ. Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am 2008; 17(4): 739–52PubMedCrossRef Stigler KA, McDougle CJ. Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am 2008; 17(4): 739–52PubMedCrossRef
24.
Zurück zum Zitat Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009; 48(11): 1110–9PubMedCrossRef Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009; 48(11): 1110–9PubMedCrossRef
25.
Zurück zum Zitat Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89(5): 485–91PubMed Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89(5): 485–91PubMed
26.
Zurück zum Zitat Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptom responses to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003; 42(12): 1443–50PubMedCrossRef Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptom responses to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003; 42(12): 1443–50PubMedCrossRef
27.
Zurück zum Zitat Matson JL. Applied behavior analysis for children with autism spectrum disorders. New York (NY): Springer, 2009CrossRef Matson JL. Applied behavior analysis for children with autism spectrum disorders. New York (NY): Springer, 2009CrossRef
28.
Zurück zum Zitat Neidert PL, Dozier CL, Iwata BA, et al. Behavior analysis in intellectual and developmental disabilities. Psychol Serv 2010; 7(2): 103–13CrossRef Neidert PL, Dozier CL, Iwata BA, et al. Behavior analysis in intellectual and developmental disabilities. Psychol Serv 2010; 7(2): 103–13CrossRef
29.
Zurück zum Zitat Weeden M, Ehrhardt K, Poling A. Conspicuous by their absence: studies comparing and combining risperidone and applied behavior analysis to reduce challenging behavior in children with autism. Res Autism Spectr Disord 2009; 3(4): 905–12CrossRef Weeden M, Ehrhardt K, Poling A. Conspicuous by their absence: studies comparing and combining risperidone and applied behavior analysis to reduce challenging behavior in children with autism. Res Autism Spectr Disord 2009; 3(4): 905–12CrossRef
30.
Zurück zum Zitat Reichow B, Volkmar FR. Social skills interventions for individuals with autism: evaluation for evidence-based practices within a best evidence synthesis framework. J Autism Dev Disord 2010; 40(2): 149–66PubMedCrossRef Reichow B, Volkmar FR. Social skills interventions for individuals with autism: evaluation for evidence-based practices within a best evidence synthesis framework. J Autism Dev Disord 2010; 40(2): 149–66PubMedCrossRef
31.
Zurück zum Zitat Koegel RL, Koegel LK, McNerney EK. Pivotal areas in intervention for autism. J Clin Child Psychol 2001; 30(1): 19–32PubMedCrossRef Koegel RL, Koegel LK, McNerney EK. Pivotal areas in intervention for autism. J Clin Child Psychol 2001; 30(1): 19–32PubMedCrossRef
32.
Zurück zum Zitat Virués-Ortega J. Applied behavior analytic intervention for autism in early childhood: meta-analysis, meta-regression and dose-response meta-analysis of multiple outcomes. Clin Psychol Rev 2010; 30(4): 387–99PubMedCrossRef Virués-Ortega J. Applied behavior analytic intervention for autism in early childhood: meta-analysis, meta-regression and dose-response meta-analysis of multiple outcomes. Clin Psychol Rev 2010; 30(4): 387–99PubMedCrossRef
33.
Zurück zum Zitat O’Conner AB, Healy O. Long-term post-intensive behavioral intervention outcomes for five children with autism spectrum disorder. Res Autism Spectr Disord 2010; 4(4): 594–604CrossRef O’Conner AB, Healy O. Long-term post-intensive behavioral intervention outcomes for five children with autism spectrum disorder. Res Autism Spectr Disord 2010; 4(4): 594–604CrossRef
34.
Zurück zum Zitat Campbell JM. Efficacy of behavioral interventions for reducing problem behavior in persons with autism: a quantitative synthesis of single-subject research. Res Dev Disabil 2003; 24(2): 120–38PubMedCrossRef Campbell JM. Efficacy of behavioral interventions for reducing problem behavior in persons with autism: a quantitative synthesis of single-subject research. Res Dev Disabil 2003; 24(2): 120–38PubMedCrossRef
35.
Zurück zum Zitat Lang R, Didden R, Machalicek W, et al. Behavioral treatment of chronic skin-picking in individuals with developmental disabilities: a systematic review. Res Dev Disabil 2010; 31(2): 304–15PubMedCrossRef Lang R, Didden R, Machalicek W, et al. Behavioral treatment of chronic skin-picking in individuals with developmental disabilities: a systematic review. Res Dev Disabil 2010; 31(2): 304–15PubMedCrossRef
36.
Zurück zum Zitat Hollander E, Phillips AT, Yeh CC. Targeted treatments for symptom domains in child and adolescent autism. Lancet 2003; 362(9385): 732–4PubMedCrossRef Hollander E, Phillips AT, Yeh CC. Targeted treatments for symptom domains in child and adolescent autism. Lancet 2003; 362(9385): 732–4PubMedCrossRef
37.
Zurück zum Zitat McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41(8): 921–7PubMedCrossRef McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41(8): 921–7PubMedCrossRef
38.
Zurück zum Zitat West L, Waldrop J, Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009; 23(2): 75–89PubMedCrossRef West L, Waldrop J, Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009; 23(2): 75–89PubMedCrossRef
39.
Zurück zum Zitat Canitano R, Scandurra V. Psychopharmacology in autism: an update. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(1): 18–28PubMedCrossRef Canitano R, Scandurra V. Psychopharmacology in autism: an update. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(1): 18–28PubMedCrossRef
40.
Zurück zum Zitat Aman MG, Van Bourgondien M, Wolford PL, et al. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry 1995; 34(12): 1672–81PubMedCrossRef Aman MG, Van Bourgondien M, Wolford PL, et al. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry 1995; 34(12): 1672–81PubMedCrossRef
41.
Zurück zum Zitat Martin A, Scahill L, Klin A, et al. High-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 1999; 38(7): 923–31PubMedCrossRef Martin A, Scahill L, Klin A, et al. High-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 1999; 38(7): 923–31PubMedCrossRef
42.
Zurück zum Zitat Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am 2008; 17(4): 787–801PubMedCrossRef Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am 2008; 17(4): 787–801PubMedCrossRef
43.
Zurück zum Zitat Mahan S, Holloway J, Bamburg JW, et al. An examination of psychotropic medication side effects: does taking a greater number of psychotropic medications from different classes affect presentation of side effects in adults with ID? Res Dev Disabil 2010; 31(6): 1561–9PubMedCrossRef Mahan S, Holloway J, Bamburg JW, et al. An examination of psychotropic medication side effects: does taking a greater number of psychotropic medications from different classes affect presentation of side effects in adults with ID? Res Dev Disabil 2010; 31(6): 1561–9PubMedCrossRef
44.
Zurück zum Zitat McDougle CJ, Stigler KA, Erickson CA, et al. Pharmacology of autism. Clin Neurosci Res 2006; 6(3–4): 179–88CrossRef McDougle CJ, Stigler KA, Erickson CA, et al. Pharmacology of autism. Clin Neurosci Res 2006; 6(3–4): 179–88CrossRef
45.
Zurück zum Zitat Deokar AM, Huff M, Omar HA. Clinical management of adolescents with autism. Pediatr Clin North Am 2008; 55(5): 1147–57PubMedCrossRef Deokar AM, Huff M, Omar HA. Clinical management of adolescents with autism. Pediatr Clin North Am 2008; 55(5): 1147–57PubMedCrossRef
46.
Zurück zum Zitat McDougle CJ, Brodkin ES, Yeung PP, et al. Risperidone in adults with autism or pervasive developmental disorders. J Child Adolesc Psychopharmacol 1995; 5(4): 273–82CrossRef McDougle CJ, Brodkin ES, Yeung PP, et al. Risperidone in adults with autism or pervasive developmental disorders. J Child Adolesc Psychopharmacol 1995; 5(4): 273–82CrossRef
47.
Zurück zum Zitat McDougle CJ, Holmes JP, Carlson RC, et al. A double-blind placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998; 55(7): 633–41PubMedCrossRef McDougle CJ, Holmes JP, Carlson RC, et al. A double-blind placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998; 55(7): 633–41PubMedCrossRef
48.
Zurück zum Zitat Potenza MN, Holmes JP, Kanes SJ, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Child Adolesc Psychopharmacol 1999; 19(1): 37–44 Potenza MN, Holmes JP, Kanes SJ, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Child Adolesc Psychopharmacol 1999; 19(1): 37–44
49.
Zurück zum Zitat Oliver-Africano P, Murphy D, Tyrer P. Aggressive behaviors in adults with intellectual disability: defining the role of drug treatment. CNS Drugs 2009; 23(11): 903–13PubMedCrossRef Oliver-Africano P, Murphy D, Tyrer P. Aggressive behaviors in adults with intellectual disability: defining the role of drug treatment. CNS Drugs 2009; 23(11): 903–13PubMedCrossRef
50.
Zurück zum Zitat Remington G, Sloman L, Konstantareas M, et al. Clomi-pramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001; 21(4): 440–4PubMedCrossRef Remington G, Sloman L, Konstantareas M, et al. Clomi-pramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001; 21(4): 440–4PubMedCrossRef
51.
Zurück zum Zitat Cook EH, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31(4): 739–45PubMedCrossRef Cook EH, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31(4): 739–45PubMedCrossRef
52.
Zurück zum Zitat Iwata BA, Dorsey MF, Slifer KJ, et al. Toward a function analysis of self-injury. Anal Intervention Dev Disabil 1982; 2(1): 3–20CrossRef Iwata BA, Dorsey MF, Slifer KJ, et al. Toward a function analysis of self-injury. Anal Intervention Dev Disabil 1982; 2(1): 3–20CrossRef
54.
Zurück zum Zitat Matson JL, Bamburg JW, Cherry KE. A validity study on the Questions About Behavioral Function (QABF) Scale: predicting treatment success for self-injury, aggression, and stereotypies. Res Dev Disabil 1999; 20(2): 163–76PubMedCrossRef Matson JL, Bamburg JW, Cherry KE. A validity study on the Questions About Behavioral Function (QABF) Scale: predicting treatment success for self-injury, aggression, and stereotypies. Res Dev Disabil 1999; 20(2): 163–76PubMedCrossRef
55.
Zurück zum Zitat Hellings JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 2001; 11(3): 229–38PubMedCrossRef Hellings JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 2001; 11(3): 229–38PubMedCrossRef
56.
Zurück zum Zitat Matson JL. Matson Evaluation of Drug Side-effects (MEDS). Baton Rouge (LA): Disability Consultants, LLC Matson JL. Matson Evaluation of Drug Side-effects (MEDS). Baton Rouge (LA): Disability Consultants, LLC
57.
Zurück zum Zitat Advocate CD, Mayville EA, Matson JL. Side effects of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Res Dev Disabil 2000; 21(1): 75–84CrossRef Advocate CD, Mayville EA, Matson JL. Side effects of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Res Dev Disabil 2000; 21(1): 75–84CrossRef
58.
Zurück zum Zitat Holden B, Gitlesen JP. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. Res Dev Disabil 2004; 25: 509–21PubMedCrossRef Holden B, Gitlesen JP. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. Res Dev Disabil 2004; 25: 509–21PubMedCrossRef
59.
Zurück zum Zitat Handen BL, Lubetsky M. Pharmacotherapy in autism and related disorders. Sch Psychol Q 2005; 20(2): 155–71CrossRef Handen BL, Lubetsky M. Pharmacotherapy in autism and related disorders. Sch Psychol Q 2005; 20(2): 155–71CrossRef
60.
Zurück zum Zitat Howlin P. Interventions and outcomes in autism. In: Singh NN, Ollendick TH, Singh AN, editors. International perspectives on child and adolescent mental health. Vol. 2. San Diego (CA): Elsevier Science, 2002: 69–99 Howlin P. Interventions and outcomes in autism. In: Singh NN, Ollendick TH, Singh AN, editors. International perspectives on child and adolescent mental health. Vol. 2. San Diego (CA): Elsevier Science, 2002: 69–99
61.
Zurück zum Zitat Bradley E, Bolton P. Episodic psychiatric disorders in teenagers with learning disabilities with and without autism. Br J Psychiatry 2006; 189: 361–6PubMedCrossRef Bradley E, Bolton P. Episodic psychiatric disorders in teenagers with learning disabilities with and without autism. Br J Psychiatry 2006; 189: 361–6PubMedCrossRef
62.
Zurück zum Zitat Eaves LC, Ho HH. Young adult outcome of autism spectrum disorders. J Autism Dev Disord 2008; 38(4): 739–47PubMedCrossRef Eaves LC, Ho HH. Young adult outcome of autism spectrum disorders. J Autism Dev Disord 2008; 38(4): 739–47PubMedCrossRef
63.
Zurück zum Zitat King BH, Bostic JQ. An update on pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2006; 15(1): 161–75 King BH, Bostic JQ. An update on pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2006; 15(1): 161–75
64.
Zurück zum Zitat Nevels RM, Dehon EE, Alexander K, et al. Psycho-pharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol 2010; 18(2): 184–201PubMedCrossRef Nevels RM, Dehon EE, Alexander K, et al. Psycho-pharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol 2010; 18(2): 184–201PubMedCrossRef
65.
Zurück zum Zitat Hollander E, Soorya L, Wasserman S, et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. J Neuropsychopaharmacology 2005; 9(2): 209–13 Hollander E, Soorya L, Wasserman S, et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. J Neuropsychopaharmacology 2005; 9(2): 209–13
66.
Zurück zum Zitat Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006; 85(1): 254–6PubMedCrossRef Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006; 85(1): 254–6PubMedCrossRef
67.
Zurück zum Zitat Malone RP, Maislin G, Chondhury MS, et al. Risperidone treatment in children and adolescents with autism: short-and long-term safety and effectiveness. J Am Acad Child Psychiatry 2002; 41(2): 140–7CrossRef Malone RP, Maislin G, Chondhury MS, et al. Risperidone treatment in children and adolescents with autism: short-and long-term safety and effectiveness. J Am Acad Child Psychiatry 2002; 41(2): 140–7CrossRef
Metadaten
Titel
Issues in the Management of Challenging Behaviours of Adults with Autism Spectrum Disorder
verfasst von
Prof. Johnny L. Matson, PhD
Megan Sipes
Jill C. Fodstad
Mary E. Fitzgerald
Publikationsdatum
01.07.2011
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 7/2011
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11591700-000000000-00000

Weitere Artikel der Ausgabe 7/2011

CNS Drugs 7/2011 Zur Ausgabe

Therapy in Practice

Transdermal Rivastigmine

Adis Drug Profile

Vilazodone

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.